+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-08-19Number of Pages: 185

Veterinary Vaccines Market (Animal Type - Companion Animals (Equine, Canine, and Feline) and Livestock Animals (Bovine, Ovine, Porcine, and Poultry); Technology Type - Inactivated Vaccines, Live Attenuated Vaccines, Conjugate Vaccines, and Toxoid Vaccines) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

A vast surge in the prevalence of zoonotic diseases, increased expenditures on the health and wellness of companion animals by pet lovers, and efforts by government and non-government organizations to educate masses about animal diseases and their effective treatment have collectively fueled the global veterinary vaccines market in the past few years. In the next few years, rising investments by key vendors on R&D activities are expected to lead to the development of highly effective varieties of vaccines such as subunit vaccines, DNA vaccines, and recombinant vaccines. This will have a huge impact on the overall growth prospects of the global veterinary vaccines market.

Transparency Market Research states that the global veterinary vaccines market, which held an opportunity worth US$6.27 bn in 2015, will exhibit a healthy 6.9% CAGR from 2016 through 2024, and rise to a valuation of US$11.40 bn by 2024.

Live Attenuated Vaccines Emerge as Leading Contributor to Market’s Revenues

Of the key varieties of veterinary vaccines available in the global market, the segment of live attenuated vaccines presently dominates. The segment held a share of more than 44% in the global market in 2015. Expected to expand at a healthy 6.8% CAGR over the period between 2016 and 2024, the segment is expected to retain its dominance in the global market in the next few years as well. Factors such as easy transport, durability, affordability, safety, and ease of administration work in favor of these vaccine types.

As the production of live attenuated vaccines incurs comparatively low costs than inactivated vaccines and can be produced in bulk, their market is expected to flourish especially in developing regions. Over the period between 2016 and 2024, however, the market for technologically advanced product varieties such as DNA vaccines, subunit vaccines, and recombinant vaccines is expected to expand at the fastest CAGR of 9.2%. Factors such as high level of safety and no use of adjuvants will help these vaccines gain increased attention from pet and farm animal owners.

veterinary-vaccines-market

 

North America Leads but Emerging Economies to Present Promising Growth Opportunities

North America is presently the key regional market for veterinary vaccines, accounting for nearly 37% of the overall revenues of the global veterinary vaccines market in 2015. The vast rise in pet ownership in the region, especially in the U.S., which has the world’s largest number of pets, is central to the massive demand for veterinary vaccines in the region. The market for veterinary vaccines in North America is also driven owing to the strict regulations put in place by the federal government mandating vaccination against certain viruses such as parvovirus, rabies, and adenovirus. Continuous research and progress in the field of veterinary immunology and immunopathology have also kept the region at the forefront of the global veterinary vaccines market.

Though the North America veterinary vaccines market will continue to be in a commanding position over the forecasting horizon in terms of revenue contribution, emerging markets such as Latin America, Asia Pacific, and Middle East and Africa are expected to provide the most promising returns. The vast rise in the number of companion and farm animals across these regions, rising awareness about vaccination among the population, and the rise in prevalence of zoonotic disease will drive the markets for veterinary vaccines in these regions. The market in Asia Pacific will exhibit a strong CAGR of 8.4% over the period between 2016 and 2024.

Some of the key vendors in the global veterinary vaccines market are Ceva Santé Animale, Bayer AG, Bimeda, Inc., Merck Animal Health, Sanofi (Merial Animal Health), Boehringer Ingelheim GmbH, Eli Lilly and Company (Elanco Animal Health), Virbac, and Zoetis, Inc.

Chapter 1 Preface
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Key Questions Answered

Chapter 2 Assumptions and Research Methodology
2.1 Report Assumptions
2.2 Acronyms Used
2.3 Research Methodology

Chapter 3 Executive Summary 
3.1 Global Veterinary Vaccines Market Snapshot
3.2 Market Opportunity Map

Chapter 4 Market Overview
4.1 Product Overview
4.2 Key Industry Events
4.3 Disease Outbreak Globally: Livestock Animals Disease
4.4 Main (Vector Borne Disease) VBDs affecting livestock
4.5 List of countries representing each virus pool (FMD) for the period 2010–2014 
4.6 Animal Population (Mn), by Country in 2015
4.7 Regulatory Scenario

Chapter 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 White Space Analysis

Chapter 6 Veterinary Vaccines Market Analysis, by Technology Type, (US$ Mn) 2014–2024
6.1 Key Findings
6.2 Introduction
6.3 Inactivated Vaccines
6.4 Live Attenuated Vaccines
6.5 Conjugate Vaccines
6.6 Toxoid Vaccines
6.7 Recombinant Vaccines
6.8 DNA Vaccines
6.9 Key Trends
6.10 Veterinary Vaccines Market Attractiveness Analysis, by Technology Type, 2015

Chapter 7 Veterinary Vaccines Market Analysis, by Animal Type, (US$ Mn), 2014–2024
7.1 Key Findings
7.2 Introduction
7.3 Veterinary vaccines (companion animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2014–2024
     7.3.1 Equine
     7.3.2 Canine
     7.3.3 Feline
7.4 Veterinary vaccines (livestock animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2014–2024
     7.4.1 Bovine
     7.4.2 Ovine
     7.4.3 Porcine
     7.4.4 Poultry
7.5 Key Trends
7.6 Veterinary Vaccines Market Attractiveness Analysis, by Animal Type

Chapter 8 Veterinary Vaccines Market Analysis, by Region, (US$ Mn), 2014–2024
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Latin America
8.5 Middle East & Africa
8.6 Geographical Scenario
8.7 Veterinary Vaccines Market Attractiveness Analysis, by Region, 2015

Chapter 9 North America Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024
9.1 North America Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2014–2024
     9.1.1 Inactivated Vaccines
     9.1.2 Conjugate Vaccines
     9.1.3 Live Attenuated Vaccines
     9.1.4 Toxoid Vaccines
     9.1.5 Other Vaccines
9.2 North America Veterinary Vaccines Market Value Share Analysis, by Animal Type, (US$ Mn), 2014–2024
     9.2.1 Animal Type
             9.2.1.1 Companion Animals
                       9.2.1.1.1 Equine 
                       9.2.1.1.2 Canine 
                       9.2.1.1.3 Feline 
             9.2.1.2 Livestock Animals
                       9.2.1.2.1 Bovine
                       9.2.1.2.2 Ovine 
                       9.2.1.2.3 Porcine 
                       9.2.1.2.4 Poultry 
                       9.2.1.2.5 Others 
9.3 U.S. Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024
9.4 Canada Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024

Chapter 10 Europe Veterinary vaccines Market Revenue Analysis, (US$ Mn), 2014–2024
10.1 Europe Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2014–2024
     10.1.1 Inactivated Vaccines
     10.1.2 Conjugate Vaccines
     10.1.3 Live Attenuated Vaccines
     10.1.4 Toxoid Vaccines
     10.1.5 Other Vaccines
10.2 Europe Veterinary Vaccines Market Value Share Analysis, by Animal Type, (US$ Mn), 2014–2024
     10.2.1 Animal Type
             10.2.1.1 Companion Animals
                       10.2.1.1.1 Equine 
                       10.2.1.1.2 Canine 
                       10.2.1.1.3 Feline 
             10.2.1.2 Livestock Animals
                       10.2.1.2.1 Bovine
                       10.2.1.2.2 Ovine 
                       10.2.1.2.3 Porcine 
                       10.2.1.2.4 Poultry 
                       10.2.1.2.5 Others 
10.3 Europe Veterinary Vaccines Market Value Share Analysis, by Country, (US$ Mn), 2014–2024
10.4 Germany Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024
10.5 U.K. Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024

Chapter 11 Asia Pacific Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024
11.1 Asia Pacific Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2014–2024
     11.1.1 Inactivated Vaccines
     11.1.2 Conjugate Vaccines
     11.1.3 Live Attenuated Vaccines
     11.1.4 Toxoid Vaccines
     11.1.5 Other Vaccines
11.2 Asia Pacific Veterinary Vaccines Market Value Share Analysis, by Animal Type, (US$ Mn), 2014–2024
     11.2.1 Animal Type
             11.2.1.1 Companion Animals
                       11.2.1.1.1 Equine 
                       11.2.1.1.2 Canine 
                       11.2.1.1.3 Feline 
             11.2.1.2 Livestock Animals
                       11.2.1.2.1 Bovine
                       11.2.1.2.2 Ovine 
                       11.2.1.2.3 Porcine 
                       11.2.1.2.4 Poultry 
                       11.2.1.2.5 Others 
11.3 Asia Pacific Veterinary Vaccines Market Value Share Analysis, by Country, (US$ Mn), 2014–2024
11.4 China Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024
11.5 Japan Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024

Chapter 12 Latin America Veterinary vaccines Market Revenue Analysis, (US$ Mn), 2014–2024
12.1 Latin America Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2014–2024
     12.1.1 Inactivated Vaccines
     12.1.2 Conjugate Vaccines
     12.1.3 Live Attenuated Vaccines     
     12.1.4 Toxoid Vaccines
     12.1.5 Other Vaccines
12.2 Latin America Veterinary Vaccines Market Value Share Analysis, by Animal Type, (US$ Mn), 2014–2024
     12.2.1 Animal Type
             12.2.1.1 Companion Animals
                       12.2.1.1.1 Equine 
                       12.2.1.1.2 Canine 
                       12.2.1.1.3 Feline 
             12.2.1.2 Livestock Animals
                       12.2.1.2.1 Bovine
                       12.2.1.2.2 Ovine 
                       12.2.1.2.3 Porcine 
                       12.2.1.2.4 Poultry 
                       12.2.1.2.5 Others 
12.3 Latin America Veterinary Vaccines Market Value Share Analysis, by Country, (US$ Mn), 2014–2024
12.4 Brazil Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024
12.5 Mexico Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024

Chapter 13 Middle East & Africa Veterinary Vaccines Market Revenue Analysis, (US$ Mn), 2014–2024
13.1 Middle East & Africa Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2014–2024
     13.1.1 Inactivated Vaccines
     13.1.2 Conjugate Vaccines
     13.1.3 Live Attenuated Vaccines
     13.1.4 Toxoid Vaccines
     13.1.5 Other Vaccines
13.2 Middle East & Africa Veterinary Vaccines Market Value Share Analysis, by Animal Type, (US$ Mn), 2014–2024
     13.2.1 Animal Type
             13.2.1.1 Companion Animals
                       13.2.1.1.1 Equine 
                       13.2.1.1.2 Canine 
                       13.2.1.1.3 Feline 
             13.2.1.2 Livestock Animals
                       13.2.1.2.1 Bovine
                       13.2.1.2.2 Ovine 
                       13.2.1.2.3 Porcine 
                       13.2.1.2.4 Poultry 
                       13.2.1.2.5 Others 
13.3 Middle East & Africa Veterinary Vaccines Market Value Share Analysis, by Country, (US$ Mn), 2014–2024
13.4 Saudi Arabia Veterinary Vaccines Market Analysis, (US$ Mn), 2014–2024

Chapter 14 Competitive Landscape
14.1 Veterinary Vaccine Market Share Analysis, by Company, (2015)
14.2 Competition Matrix
     14.2.1 Bayer AG 
     14.2.2 Bimeda, Inc. 
     14.2.3 Boehringer Ingelheim GmbH 
     14.2.4 Ceva Santé Animale 
     14.2.5 Eli Lilly and Company (Elanco Animal Health) 
     14.2.6 Merck Animal Health 
     14.2.7 Sanofi S.A. (Merial Animal Health) 
     14.2.8 Virbac 
     14.2.9 Zoetis, Inc.
14.3 Company Profiles
     14.3.1 Bayer AG
             14.3.1.1 Company Details
             14.3.1.2 Company Description
             14.3.1.3 Business Overview
             14.3.1.4 SWOT Analysis
             14.3.1.5 Financials
             14.3.1.6 Strategic Overview
             14.3.1.7 Product Portfolio
             14.3.1.8 Recent Developments 
     14.3.2 Bimeda, Inc. 
             14.3.2.1 Company Details
             14.3.2.2 Company Description
             14.3.2.3 Business Overview
             14.3.2.4 SWOT Analysis
             14.3.2.5 Financials
             14.3.2.6 Strategic Overview
             14.3.2.7 Product Portfolio
             14.3.2.8 Recent Developments 
     14.3.3 Boehringer Ingelheim GmbH 
             14.3.3.1 Company Details
             14.3.3.2 Company Description
             14.3.3.3 Business Overview
             14.3.3.4 SWOT Analysis
             14.3.3.5 Financials
             14.3.3.6 Strategic Overview
             14.3.3.7 Product Portfolio
             14.3.3.8 Recent Developments 
     14.3.4 Ceva Santé Animale 
             14.3.4.1 Company Details
             14.3.4.2 Company Description
             14.3.4.3 Business Overview
             14.3.4.4 SWOT Analysis
             14.3.4.5 Financials
             14.3.4.6 Strategic Overview
             14.3.4.7 Product Portfolio
             14.3.4.8 Recent Developments 
     14.3.5 Eli Lilly and Company (Elanco Animal Health) 
             14.3.5.1 Company Details
             14.3.5.2 Company Description
             14.3.5.3 Business Overview
             14.3.5.4 SWOT Analysis
             14.3.5.5 Financials
             14.3.5.6 Strategic Overview
             14.3.5.7 Product Portfolio
             14.3.5.8 Recent Developments 
     14.3.6 Merck Animal Health 
             14.3.6.1 Company Details
             14.3.6.2 Company Description
             14.3.6.3 Business Overview
             14.3.6.4 SWOT Analysis
             14.3.6.5 Financials
             14.3.6.6 Strategic Overview
             14.3.6.7 Product Portfolio
             14.3.6.8 Recent Developments 
     14.3.7 Sanofi S.A. (Merial Animal Health) 
             14.3.7.1 Company Details
             14.3.7.2 Company Description
             14.3.7.3 Business Overview
             14.3.7.4 SWOT Analysis
             14.3.7.5 Financials
             14.3.7.6 Strategic Overview
             14.3.7.7 Product Portfolio
             14.3.7.8 Recent Developments 
     14.3.8 Virbac 
             14.3.8.1 Company Details
             14.3.8.2 Company Description
             14.3.8.3 Business Overview
             14.3.8.4 SWOT Analysis
             14.3.8.5 Financials
             14.3.8.6 Strategic Overview
             14.3.8.7 Product Portfolio
             14.3.8.8 Recent Developments 
     14.3.9 Zoetis, Inc.
             14.3.9.1 Company Details
             14.3.9.2 Company Description
             14.3.9.3 Business Overview
             14.3.9.4 SWOT Analysis
             14.3.9.5 Financials
             14.3.9.6 Strategic Overview
             14.3.9.7 Product Portfolio
             14.3.9.8 Recent Developments 

List of Figures

FIG. 1 Global Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2015 and 2024
FIG. 2 Global Inactivated Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 3 Global Live Attenuated Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 4 Global Conjugate Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 5 Global Toxoid Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 6 Global Recombinant Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 7 Global DNA Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 8 Global Veterinary Vaccines (companion animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 9 Global Equine Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 10 Global Canine Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 11 Global Feline Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 12 Global Companion Animal Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 13 Global Veterinary Vaccines (livestock animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 14 Global Bovine Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 15 Global Ovine Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 16 Global Porcine Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 17 Global Poultry Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 18 Global Veterinary Vaccines Market Value Share Analysis, by Region, 2015 and 2024
FIG. 19 Veterinary Vaccines Market Attractiveness Analysis, by Region, (US$ Mn), 2014–2024
FIG. 20 Veterinary Vaccines Market Attractiveness Analysis, by Technology Type, (US$ Mn), 2014–2024
FIG. 21 Veterinary Vaccines Market Attractiveness Analysis, by Animal Type, (US$ Mn), 2014–2024
FIG. 22 North America Veterinary Vaccines (companion animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 23 North America Veterinary Vaccines (livestock animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 24 North America Veterinary Vaccines (livestock animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 25 North America Market Value Share Analysis, by Country, (US$ Mn), 2015 and 2024
U.S. Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 26 U.S. Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024 
FIG. 27 Canada Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 28 Europe Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2015 and 2024
FIG. 29 Europe Veterinary Vaccines (companion animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024 
FIG. 30 Europe Veterinary Vaccines (livestock animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 31 Europe Veterinary Vaccines Market Value Share Analysis, by Country, (US$ Mn), 2015 and 2024
FIG. 32 Germany Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 33 U.K. Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 34 Asia Pacific Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2015 and 2024
FIG. 35 Asia Pacific Veterinary Vaccines (companion animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 36 Asia Pacific Veterinary Vaccines (livestock animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 37 Asia Pacific Veterinary Vaccines Market Value Share Analysis, by Country, (US$ Mn) 2015 and 2024
FIG. 38 China Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 39 Japan Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 40 Latin America Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2015 and 2024
FIG. 41 Latin America Veterinary Vaccines (companion animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 42 Latin America Veterinary Vaccines (livestock animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 43 Latin America Market Value Share Analysis, by Country, (US$ Mn), 2015 and 2024
FIG. 44 Brazil Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 45 Mexico Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 46 Middle East & Africa Veterinary Vaccines Market Value Share Analysis, by Technology Type, (US$ Mn), 2015 and 2024
FIG. 47 Middle East & Africa Veterinary Vaccines (companion animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 48 Middle East & Africa Veterinary Vaccines (livestock animals) Market Value Share Analysis, by Animal Type, (US$ Mn), 2015 and 2024
FIG. 49 Saudi Arabia Veterinary Vaccines Market Revenue, (US$ Mn), 2014–2024
FIG. 50 Global Veterinary Vaccines Market Share Analysis, by Company (%) (2015)

List of Tables

Table 1. Global Veterinary Vaccines Market Size Forecast, by Technology Type, (US$ Mn), 2014–2024
Table 2. Global Veterinary Vaccines (companion animals) Market Size Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 3. Global Veterinary Vaccines (livestock animals) Market Size Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 4. Global Veterinary Vaccines Market Size Forecast, by Region, (US$ Mn), 2014–2024
Table 5. North America Veterinary Vaccines Market Size Forecast, by Technology Type, (US$ Mn), 2014–2024
Table 6. Global Veterinary Vaccines (companion animals) Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 7. Global Veterinary Vaccines (livestock animals) Market Size Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 8. North America Veterinary Vaccines Market Size Forecast, by Country, (US$ Mn), 2014–2024
Table 9. Europe Veterinary Vaccines Market Size Forecast, by Technology Type, (US$ Mn), 2014–2024
Table 10. Europe Veterinary Vaccines (companion animals) Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 11. Europe Veterinary Vaccines (livestock animals) Market Size (US$ Mn) Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 12. Europe Veterinary Vaccines Market Size Forecast, by Country, (US$ Mn), 2014–2024
Table 13. Asia Pacific Veterinary Vaccines Market Size Forecast, by Technology Type, (US$ Mn), 2014–2024
Table 14. Asia Pacific Veterinary Vaccines (companion animals) Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 15. Asia Pacific Veterinary Vaccines (livestock animals) Market Size Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 16. Asia Pacific Veterinary Vaccines Market Size Forecast, by Country, (US$ Mn), 2014–2024
Table 17. Latin America Veterinary Vaccines Market Size (US$ Mn) Forecast, by Technology Type, (US$ Mn), 2014–2024
Table 18. Latin America Veterinary Vaccines (companion animals) Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 19. Latin America Veterinary Vaccines (livestock animals) Market Size (US$ Mn) Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 20. Latin America Veterinary Vaccines Market Size Forecast, by Country, (US$ Mn), 2014–2024
Table 21. Middle East & Africa Veterinary Vaccines Market Size Forecast, by Technology Type, (US$ Mn), 2014–2024 
Table 22. Middle East & Africa Veterinary Vaccines (companion animals) Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 23. Middle East & Africa Veterinary Vaccines (livestock animals) Market Size (US$ Mn) Forecast, by Animal Type, (US$ Mn), 2014–2024
Table 24. Middle East & Africa Veterinary Vaccines Market Size Forecast, by Country, (US$ Mn), 2014–2024

Global Veterinary Vaccines Market: Overview 

Veterinary vaccines often prove themselves to be live-savers for animals against diseases that are generally fatal or leave them impaired or handicapped. Veterinary vaccines thus offer protection to animals similar to the way humans are vaccinated against potentially incurable diseases. The way veterinary vaccines work may be different than human vaccines however. It is often encouraged for pet owners to vaccinate their pets regularly as it is much cheaper than opting for the treatment of a sick animal. It also helps reduce the transmission of germs and bacteria within animals and thus ensures a healthier environment for all animals and pets in an area. In the case of livestock, vaccination promotes a healthier output and prevents the transmission of harmful microorganisms to humans upon consumption of meat of animal products. The common diseases for which pets and livestock are vaccinated include brucellosis, pinkeye, E. coli, and rotavirus. 

The report on the global veterinary vaccines market offers a descriptive analysis of the factors that have been – and will be – responsible for the progress rate of the market. These factors are dissected based on the various segments available in the market for study and player diversity. The report uses all current and recent data to effectively pinpoint the situation the global veterinary vaccines market is in currently and what it will look like in the near future. The analysis of the global veterinary vaccines market is performed using tried and tested industry standards such as Porter’s Five Forces analysis and the SWOT analysis. The report also provides a highly in-depth view of the competitive landscape of the global veterinary vaccines market and its predicted future tense. 

Global Veterinary Vaccines Market: Trends and Opportunities: 

The primary driver boosting the global veterinary vaccines market is the growing consumption of animal products across the world. With a large human population associated with the demand for dairy, meat, fish, and eggs, it is necessary for the animal husbandry industry to spruce up its vaccination policies and rates. In the case of pets, the amount of pet owners in the world has also gone up considerably over the past few years. Market research points to an even higher number of pet owners by 2024. At the same time, the expenditure made by each pet owner for the health and happiness of their pets has risen significantly, further pointing to a progressively inclined rate of veterinary vaccination. 

The problem of high restrictions still persists in the global veterinary vaccines market as players are often barred from commercial entry due to the high market standards, regulatory restriction, and the high cost of research and development efforts. Many governments have stepped in, providing incentives and awareness initiatives for the sake of getting a larger population of the domesticated animal kingdom to be protected from harm. 

Global Veterinary Vaccines Market: Region-wise Outlook: 

The global veterinary vaccines market is expected to reach US$11.4 bn by 2024, after being projected at a CAGR of 6.9% from 2016 to 2024. Regionally speaking, a large chunk of this current growth rate is attributed to the high demand shown by North America and its growing populations of pet owners and livestock. The emerging economies from Asia Pacific, Latin America and the Middle East are simultaneously showing a very high growth rate in their consumption of veterinary vaccines owing to greater awareness and an increasing demand for animal products. 

Companies Mentioned in the Research Report:

The key players in the global veterinary vaccines market include Bayer AG, Boehringer Ingelheim GmbH, Bimeda, Inc., Virbac, Eli Lilly and Company (Elanco Animal Health), Ceva Santé Animale, Sanofi S.A. (Merial Animal Health), Merck Animal Health, and Zoetis, Inc. 

Key segments of the Global Veterinary Vaccines Market: 

Global Veterinary Vaccines Market, by Animal Type

  • Animal Type
    • Companion Animals
      • Equine
      • Canine
      • Feline
    • Livestock Animals
      • Bovine
      • Ovine
      • Porcine
      • Poultry
      • Others

Global Veterinary Vaccines Market, by Technology Type

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Conjugate Vaccines
  • Toxoid Vaccines
  • Other Vaccines 

Major regions analyzed under this research report are:

  • Europe
  • North America
  • Asia Pacific
  • Rest of the World 

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments


 
 
Back To Top